

**Committee on Energy and Commerce**  
**U.S. House of Representatives**  
 Witness Disclosure Requirement - "Truth in Testimony"  
 Required by House Rule XI, Clause 2(g)

1. Your Name: <u>Luciana Borio, M.D.</u>		
2. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No <input checked="" type="checkbox"/>
3. Are you testifying on behalf of an entity that is not a government entity?	Yes	No <input checked="" type="checkbox"/>
4. Other than yourself, please list which entity or entities you are representing:		
5. Please list any Federal grants or contracts (including subgrants or subcontracts) that <u>you or the entity you represent have received on or after October 1, 2011:</u>		
6. If your answer to the question in item 3 in this form is "yes," please describe your position or representational capacity with the entity or entities you are representing:		
7. If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?	Yes	No <input checked="" type="checkbox"/>
8. If the answer to the question in item 3 is "yes," please list any Federal grants or contracts (including subgrants or subcontracts) that were received by the entities listed under the question in item 4 on or after October 1, 2011, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed:		
9. Please attach your curriculum vitae to your completed disclosure form.		

Signature: [REDACTED]

Date: 11/18/14

Dr. Luciana Borio serves as the Assistant Commissioner for Counterterrorism Policy and the Director of the Office of Counterterrorism and Emerging Threats at Food and Drug Administration. She provides leadership, coordination, and oversight for FDA's national and global health security, counterterrorism, and emerging threat portfolios and works in collaboration with other U.S. government agencies to help facilitate the development and availability of medical countermeasures to respond to public health emergencies. She also leads FDA's Medical Countermeasures Initiative, a key component of a broad U.S. government program to improve the United States' capacity to respond quickly and effectively to public health emergencies. Dr. Borio was instrumental in coordinating FDA's response to the 2009 H1N1 influenza pandemic and continues to coordinate FDA's preparedness and response activities for emerging threats, such as the avian influenza A (H7N9) virus and the Middle East Respiratory Syndrome coronavirus (MERS-CoV) and the Ebola outbreak in West Africa.

